Therapeutics for suppressing DUX4 have reached clinical trials, including the p38 inhibitor losmapimod.26 However, losmapimod did not significantly change the primary outcome measure: DUX4 target gene expression in FSHD muscle, despite improvement in secondary functional outcomes. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.